Skip to main content
. Author manuscript; available in PMC: 2017 Oct 1.
Published in final edited form as: Brain Behav Immun. 2016 Jun 16;57:106–115. doi: 10.1016/j.bbi.2016.06.011

Fig. 1. Generation of MDA-MB-231HM breast cancer cells deficient in β2AR.

Fig. 1

(a) Quantification of ADRB mRNA transcript levels using qRT-PCR in MDA-MB-231HM cells transduced with shRNA scramble sequence (control) or shRNA targeting ADRB2 (shADRB2a and shADRB2b) (n = 4). ND: not detected. (b) Quantification of cAMP accumulation in scramble control, shADRB2a and shADRB2b tumor cells in response to increasing concentrations of the β2AR selective-agonist formoterol (n = 3). (c) Proliferation of control, shADRB2a and shADRB2b tumor cells (n = 3). Data represent mean ± standard error. **p < 0.01 by one-way ANOVA with post hoc Tukey’s planned comparison tests.